

## Iowa Medicaid

### Public Notification: Request for Comment

**To:** Individuals Who Possess Scientific or Medical Training with Respect to Drugs or Biological Products for Rare Diseases

**From:** Drug Utilization Review (DUR) Commission

**Subject:** Public Comment Regarding Drugs and Biological Products for Rare Diseases and Biological Products that are Genetically Targeted

**Notification Date:** April 1, 2025

**Required Response Date:** April 29, 2025

[House File 653](#) established a requirement for the Pharmaceutical and Therapeutics (P&T) Committee and the Drug Utilization Review (DUR) Commission to request and consider information from individuals who possess scientific or medical training with respect to drugs and biological products for rare diseases and drugs and biological products that are genetically targeted when making recommendations or determinations regarding beneficiary access.

Information is being requested for the drugs and biological products identified below which may be reviewed at an upcoming DUR meeting from individuals who possess scientific or medical training with respect to the drug, biological product, or rare disease. Please provide comment to the contact information provided below by the required response date, including a conflict of interest disclosure form. Please follow the current established processes for providing oral public comment when attending DUR meetings. Submit request to provide public comment by April 29, 2025.

Process for Written Public Comment Submission for Drugs for Rare Diseases for May 7, 2025 DUR Meeting:

- Iowa Medicaid Public Notification: Request for Comment is posted to the [Iowa Medicaid Pharmacy Website](#).
- Listserv notification is sent by Iowa Medicaid.
- Individual prepares their public comment.
- Public comment is submitted to the appropriate Iowa Medicaid contact (provided below) along with the conflict of interest disclosure form, by April 29, 2025.
- Public comment is shared with DUR Commission and included in meeting materials.
- No response will be provided to the submitted public comment.

**DUR Commission:**

Next meeting date: May 7, 2025

Contact Information: [pba\\_iadur@optum.com](mailto:pba_iadur@optum.com)

[Conflict of Disclosure Form](#)

**INFORMATION REQUEST:**

1. Duvyzat